Introduction
============

Rheumatoid arthritis (RA) is a debilitating autoimmune disease that has no clearly defined aetiology, although there is a definite genetic predisposition and associated risk factors \[[@B1]\]. The shared epitope (SE) concept in relation to genetic predisposition was first described in 1986 and has evolved from the classic HLA-DRB1\*01, HLA-DRB1\*04 and HLA-DRB1\*10 associations \[[@B2]-[@B4]\] to the identification of the RAA amino acid motif at positions 72 to 74 of the third hypervariable region of the different human leucocyte antigen (HLA)-DRB1 chains as the definitive SE \[[@B3]-[@B5]\]. This concept has been extended by Gao *et al*. \[[@B6]\] to include the amino acid residues at positions 71 and 76 and, recently, to a new classification which incorporates the modulatory activities of the amino acids at positions 70 and 71 in addition to the RAA motif at positions 72 to 74 \[[@B6]-[@B8]\].

Although the primary triggering autoantigens in RA have not been described to date, it is noteworthy that associations between the various HLA-DRB1 SE subtypes with disease susceptibility and/or severity and the presence of circulating anticitrullinated peptide antibodies have been described \[[@B9]-[@B18]\]. In addition, HLA-DRB1 SE genotyping and measurement of anticyclic citrullinated peptide antibodies (aCCP) and, to a lesser extent, rheumatoid factor (RF) have the potential to predict future development of RA \[[@B10],[@B14],[@B17],[@B19]-[@B21]\]. Taken together, these associations between HLA-DRB1 SE genotype, aCCP and disease susceptibility and/or severity appear to be compatible with the presentation of citrullinated autoantigens by HLA-DRB1 SE subtypes as an immunopathogenic mechanism in RA.

While lacking diagnostic specificity, the measurement of circulating cytokines and chemokines and acute phase reactants, combined with the detection of aCCP and RF, has the potential to predict the time until onset of clinical disease \[[@B22],[@B23]\] as well as disease severity \[[@B24]-[@B27]\]. Nonetheless, in relatively few studies have researchers undertaken a composite analysis of SE genotyping and measurement of circulating aCCP, cytokines, chemokines and acute phase reactants as a strategy not only to identify interactions between these alleles and biomarkers but also to establish which combinations of these are most strongly associated with disease severity. These issues were addressed in the current study of a cohort of predominantly African patients with RA of two years\' duration or less. To our knowledge, this is the first study to measure the frequency of the various SE subtypes according to the du Montcel classification system \[[@B7]\] in this patient population.

Materials and methods
=====================

Following approval by the Research Ethics Committees of the Faculties of Health Sciences of the University of Pretoria and University of the Witwatersrand, 143 patients who presented to the rheumatology clinics of two tertiary hospitals in the Gauteng Province of South Africa (Chris Hani Baragwanath Hospital, Soweto, and Steve Biko Academic Hospital, Pretoria) were recruited to participate in the study. Prior informed consent was obtained from all participants, all of whom met the 1987 American College of Rheumatology criteria for RA \[[@B28]\]. All of the patients were disease-modifying antirheumatic drug (DMARD)-naïve and HIV-seronegative and had RA symptoms of two years\' duration or less. The Disease Activity Score in 28 joints (DAS28) on the basis of CRP level (DAS28-CRP) was used to assess disease activity upon presentation \[[@B29],[@B30]\]. \"Erosive disease\" was defined as the presence of marginal joint erosions on standard X-rays of the hands and feet. These clinical assessments were performed by two experienced rheumatologists (BH and MA). Demographic data for this cohort are shown in Table [1](#T1){ref-type="table"}.

###### 

Demographic, laboratory and clinical data for the RA patient group (*n*= 143)

  Parameters                   Data          Median \[IQR\]        Range
  ---------------------------- ------------- --------------------- ------------
  Age (years)                  48 ± 12       48 \[41 to 56\]       20 to 75
  Females, *n*(%)              118 (82.5%)                         
  Blacks, *n*(%)               124 (86.7%)                         
  DAS28-CRP                    5.6 ± 1.3     5.7 \[4.8 to 6.7\]    2.3 to 8.7
  Disease duration (months)    12 ± 7        10 \[6 to 18\]        0 to 25
  Larsen radiographic scores   23 ± 14       19 \[14 to 28\]       1 to 66
  RF (IU/ml)                   490 ± 795     168 \[38 to 595\]     4 to 5,350
  aCCP (U/ml)                  669 ± 636     492 \[85 to 1,099\]   2 to 2,527
  CRP (μg/L)                   24 ± 32       14 \[5 to 32\]        0 to 198
  SAA (μg/ml)                  62 ± 123      14 \[5 to 65\]        1 to 882

aCCP = anticyclic citrullinated peptide antibodies; CRP = C-reactive protein; DAS28 = Disease Activity Score in 28 joints; RF = rheumatoid factor; SAA = serum amyloid A. Data are means ± SD, n (%), medians \[25th to 75th IQR\] or raw data as indicated.

Autoantibodies and acute phase reactants
----------------------------------------

Venous blood (30 ml) was collected in commercial sample test tubes containing a gel separator. The blood samples were kept at room temperature to clot and then spun at 3,000 rpm for 10 minutes), followed by collection of the serum, aliquoting and storage at -20°C until needed for analysis.

RF (composite immunoglobulin M (IgM), IgG and IgA), CRP and serum amyloid A (SAA) were assayed by nephelometry (BN ProSpec System; Siemens Healthcare Diagnostics, Deerfield, IL, USA). As per the manufacturer\'s supplier controls, RF, CRP and SAA results were considered positive when their individual concentrations exceeded 11 IU/ml, 5 μg/ml and 6.8 μg/ml, respectively. aCCP were measured using a second-generation immunofluorometric procedure using the ImmunoCAP Phadia 250 assay system with reagents and controls provided by the manufacturer (Phadia AB, Uppsala, Sweden). A concentration greater than 10 U/ml was deemed positive.

Serum cytokines, chemokines and growth factors
----------------------------------------------

Serum cytokines, chemokines and growth factors were measured using the Bio-Plex multiplex suspension array system with xMAP technology (Bio-Rad Laboratories, Hercules, CA, USA), which enables simultaneous detection and quantitation of multiple different analytes in a single sample. The system uses an array of microspheres in liquid suspension that are conjugated with a mAb specific for a target protein. A wide range of standards (0.38 to 91,756.00 pg/ml) was used to enable quantitation of the individual cytokines by using a Bio-Plex array reader (Bio-Rad Laboratories) with a dual laser detector and real-time digital signal processing. The following analytes were measured: IL-1β, IL-1Ra, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17, IFN-γ, TNF, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), chemokine (C-C motif) ligand 2 (CCL2), CCL4 and vascular endothelial growth factor (VEGF). The upper limits of normal for these analytes were calculated as the mean +2 SD for 10 healthy control subjects (five female and five male, average age 44.4 ± 15.0 years, age range 26 to 65 years).

Typing of human leucocyte antigen-DRB1 alleles
----------------------------------------------

Genomic DNA was obtained by using the Maxwell 16 System with the Maxwell 16 Blood DNA Purification Kit (Promega, Madison, WI, USA) to extract DNA from whole blood, which was collected in ethylenediaminetetraacetic acid (EDTA) sample tubes. The patients\' HLA-DRB1 alleles were determined by using a DNA-based high-resolution typing method, the LABType HD Class II DRB1 Typing Test (One Lambda Inc, Canoga Park, CA, USA), with reverse sequence-specific oligonucleotide probes and Luminex technology. The target DNA (*HLA-DRB1*gene) was amplified by PCR using group-specific primers biotinylated for detection with streptavidin R-phycoerythrin conjugate. The PCR product was then denatured and hybridised to complementary DNA probes conjugated to fluorophores. Bound DNA was detected on the Luminex system, and software (HLA Fusion&\#8482 Software Version 2.0, One Lambda, Inc.,21001 Kittridge Street, Canoga Park, CA, USA)was used to map the reaction patterns to those associated with published *HLA*gene sequences and assign the represented HLA-DRB1 alleles. HLA alleles were assigned according to the RAA amino acid sequence at positions 72-74 as SE (S) and non-SE (X), and the S group was further subdivided according to amino acid groups at positions 70 and 71 as described by du Montcel *et al*. \[[@B7]\] (see Table [2](#T2){ref-type="table"}). The International Immunogenetics Information System database \[[@B31],[@B32]\] and the Allele\*Frequencies in Worldwide Populations Net Database \[[@B33]\] were used to establish regional and ethnicity-matched HLA-DRB1 frequencies in sub-Saharan Africa. The non-SE patients with the no SE allele (XX) genotype (*n*= 12) were used as controls in the calculation of contingency tables.

###### 

Shared epitope classification according to amino acid sequence at positions 70-74

  Allele classification   Amino acid sequence positions 70 to 74   HLA-DRB1 alleles
  ----------------------- ---------------------------------------- -----------------------------------------------------------------------
  S1                      D-E-RAA                                  \*01:03, \*04:02, \*11:02-:03, \*13:01-:02, \*13:04, \*13:36, \*13:40
                          Q-A-RAA                                  \*15
  S2                      Q-K-RAA                                  \*04:01, \*04:09, \*04:13, \*04:35, \*04:66
                          D-K-RAA                                  \*13:03
  S3D                     D-R-RAA                                  \*11:01, \*11:04, \*11:27, \*12, \*13:05-:06, \*13:25, \*14:22, \*16
  S3P                     Q-R-RAA                                  \*01:01-:02, \*04:04-:05, \*04:08, \*04:10
                          R-R-RAA                                  \*10:01
  X                       Q-K-RGR                                  \*03
                          Q-R-RAE                                  \*04:03, \*04:07, \*04:11
                          D-R-RGQ                                  \*07
                          D-R-RAL                                  \*08
                          R-R-RAE                                  \*09:01, \*14:01, \*14:04

HLA = human leucocyte antigen. Data in right column from Gao *et al*. \[[@B6]\].

Statistical methods
-------------------

Descriptive and inferential statistics techniques were used in the analyses. Tests for association of contingency tables were performed using either the two-tailed Fisher\'s exact test or the χ^2^test with the Yates correction. One-way analysis of variance (ANOVA) was performed using the Kruskal-Wallis test for nonparametric data for more than two groups, or the Mann-Whitney *U*test when two groups were compared. Logistic regression was used for binary outcome variables, and the OR and corresponding 95% confidence interval were reported. *P*\< 0.05 was considered statistically significant. The analyses were done using Stata software (Stata Corp, College Station, TX, USA).

Results
=======

Human leucocyte antigen-DRB1 incidence
--------------------------------------

All of the \"classical\" RA-associated HLA-DRB1\*01, HLA-DRB1\*04 and HLA-DRB1\*10 alleles showed statistically significant ORs, with HLA-DRB1\*04 the most prominent (Table [3](#T3){ref-type="table"}), underscoring the significance of the HLA-DRB1 SE previously reported in the African population \[[@B34]-[@B38]\]. The HLA-DRB1 alleles were categorized according to the new classification as being homozygous for the SE allele (SS), heterozygous for the SE allele (SX) or XX. The majority (92%) of the patients had at least one allele associated with the amino acid motif. More than half (57%) of the patients typed were homozygous (SS), 35% were heterozygous (SX) and only 8% had no associated HLA-DRB1 allele (XX). The SS, SX and XX allele distribution among the African subgroup of the cohort (*n*= 124) was 58% (*n*= 72), 35% (*n*= 43) and 7% (*n*= 9), respectively. The other South African population groups (Caucasian, Asian and mixed ancestry) were not meaningfully represented, however.

###### 

Human leucocyte antigen-DRB1 rheumatoid arthritis-associated alleles, odds ratios and confidence intervals in the rheumatoid arthritis patient cohort

  Risk allele    RA patients, *n*(%) (*n*= 143)   Controls\*, *n*(%) (*n*= 1,104)   OR (95% CI)           *P*value
  -------------- -------------------------------- --------------------------------- --------------------- ----------
  HLA-DRB1\*01   26 (18.2)                        93 (8.4)                          2.4 (1.5 to 3.9)      0.0007
  HLA-DRB1\*04   61 (42.7)                        41 (3.7)                          19.3 (12.2 to 30.4)   \<0.0001
  HLA-DRB1\*10   10 (7.0)                         36 (3.3)                          2.2 (1.0 to 4.6)      0.0338

HLA = human leucocyte antigen; OR = odds ratio; RA = rheumatoid arthritis. \*Data from Robinson and colleagues \[[@B31],[@B32]\].

Classification of RA-associated HLA-DRB1 alleles according to the du Montcel *et al*. classification system \[[@B7]\] revealed that S2 and S3P had significantly higher allele frequencies than those found in the general sub-Saharan population \[[@B32],[@B33]\]. S3D and the non-epitope-associated alleles (X) were not significantly different in the RA groups compared to the general sub-Saharan population. As shown in Table [4](#T4){ref-type="table"}, S1 was significantly undertransmitted in our population.

###### 

Comparison of allele carrier frequencies in RA cases and controls in accordance with the du Montcel classification

  Allele   RA patients, *n*(%) (*n*= 143)   **Controls**^**\***^**, *n*(%) (*n*= 1,104)**   **Χ**^**2**^**test**   OR (95% CI)        *P*value
  -------- -------------------------------- ----------------------------------------------- ---------------------- ------------------ ----------
  S1       55 (39)                          853 (77)                                        40.3                   0.4 (0.3 to 0.5)   \<0.0001
  S2       28 (20)                          110 (10)                                        10.3                   2.0 (1.3 to 3.2)   0.0013
  S3D      38 (27)                          361 (33)                                        0.1                    0.9 (0.6 to 1.3)   0.7060
  S3P      61 (43)                          313 (28)                                        9.6                    1.6 (1.2 to 2.2)   0.0019
  X        64 (45)                          616 (56)                                        3.6                    0.8 (0.6 to 1.0)   0.0571

RA = rheumatoid arthritis. du Montcel classification is from du Montcel *et al*. \[[@B7]\]. \*Data from Robinson and colleagues \[[@B31],[@B32]\].

Relationship of shared epitope classification and autoantibodies
----------------------------------------------------------------

Analysis (by one-way ANOVA and Mann-Whitney *U*test) of the median values of autoantibodies revealed that they were generally higher in the SS group than in the SX group. Significant associations were noted for aCCP (SS vs SX vs XX; *P*= 0.0298) and for RF (SS vs XX, *P*= 0.0129; SX vs XX, *P*= 0.0273).

As X alleles have been shown to be undertransmitted in the RA cohort (that is, noncarriers of risk alleles) (see Table [4](#T4){ref-type="table"}), they were used as the control group within the RA cohort to determine the possible associations of the HLA-DRB1 genotype with RA-associated autoantibodies by comparing the total positive and negative results for the RA-associated antibodies (RF and aCCP) in the risk groups with those for the control group (XX). As shown in Table [5](#T5){ref-type="table"}, both RF and aCCP seropositivity were significantly higher in both the SS and SX groups of the total cohort in comparison with the XX control group. The data are as follows: RF (SS group vs XX control group: OR = 7.0, *P*= 0.0059, and SX group vs XX control group: OR = 6.3, *P*= 0.0126) and aCCP (SS group vs XX control group: OR = 10.2, *P*= 0.0010, and SX group vs XX control group: OR = 9.2, *P*= 0.0028).

###### 

Relationship between human leucocyte antigen-DRB1 shared epitope homozygosity or heterozygosity and risk of anticyclic citrullinated peptide antibody or rheumatoid factor seropositivity

         Total cohort (*n*= 143)   Blacks (*n*= 124)                                                                                 
  ------ ------------------------- ------------------- ------------------- -------- ------------------- -------- ------------------- --------
  RF     7.0 (1.8 to 26.6)         0.0059              6.3 (1.5 to 25.7)   0.0126   4.5 (1.0 to 19.5)   0.0537   4.1 (0.9 to 19.3)   0.0813
  aCCP   10.2 (2.6 to 40.3)        0.0010              9.2 (2.2 to 38.9)   0.0028   7.1 (1.6 to 30.4)   0.0121   6.4 (1.4 to 30.1)   0.0223

aCCP = anticyclic citrullinated peptide antibodies; HLA = human leucocyte antigen; RF = rheumatoid factor; SE = shared epitope; SS = homozygous for shared epitope allele; SX = heterozygous for shared epitope allele.

The SS and SX groups of the African patients showed a statistically significant predisposition to aCCP seropositivity compared with the XX group (SS group vs XX control group: OR = 7.01, *P*= 0.0121; SX group vs XX control group: OR = 6.4, *P*= 0.0223), and RF was also more prevalent in the SS and SX groups compared to the XX control group, although the difference was not significant (Table [5](#T5){ref-type="table"}). Stratifying the patients according to du Montcel *et al*.\'s allele classification \[[@B7]\] as SS, SX or XX therefore seems to strengthen the genetic association with the presence of aCCP, an observation which is in agreement with the findings of Huizinga *et al*. \[[@B14]\] and Klareskog *et al*. \[[@B39]\].

Further analysis was undertaken to probe the associations with the amino acids at positions 70 and 71 (S1, S2, S3D and S3P) with aCCP seropositivity by comparing noncarriers with the carrier allele groups. As shown in Table [6](#T6){ref-type="table"}, this analysis revealed significantly higher ORs in the case of the S2 and S3P allele groups and weak, albeit significant, associations with the S1, S3D and X allele groups. RF seropositivity was weakly associated with all allele groups.

###### 

Association between anticyclic citrullinated peptide antibody and rheumatoid factor with shared epitope alleles according to the du Montcel classification

                         aCCP                 RF                                 
  ---------------------- -------------------- -------------- ------------------- ----------
  S1 allele (*n*= 55)    2.9 (0.7 to 12.4)    0.2054         4.5 (1.2 to 16.9)   \*0.0291
  S2 allele (*n*= 28)    12.0 (2.4 to 59.5)   0.0019\*\*     8.3 (1.6 to 43.3)   \*0.0122
  S3D allele (*n*= 38)   7.5 (1.8 to 31.4)    0.0100\*       5.3 (1.3 to 22.7)   \*0.0246
  S3P allele (*n*= 61)   13.3 (3.2 to 54.4)   0.0003\*\*\*   4.5 (1.2 to 16.8)   \*0.0264
  X allele (*n*= 64)     4.7 (1.2 to 17.6)    0.0213\*       2.7 (0.8 to 9.8)    0.1678

aCCP = anticyclic citrullinated peptide antibodies; RF = rheumatoid factor. du Montcel classification is from du Montcel *et al*. \[[@B7]\]. OR (95% CI) and *P*values were calculated using Fisher\'s exact test to compare with SE noncarrier rheumatoid arthritis patients (*n*= 12). \**P*\< 0.05. \*\**P*≤ 0.001 and \*\*\**P*≤ 0.0003 values are highly significant.

The association between SE genotype and aCCP or RF seropositivity was further probed by categorising patients into high-risk or low-risk allele groups according to the du Montcel classification system \[[@B7]\] with the XX genotype used as a comparator. The low-risk genotype groups were (1) S1, consisting of genotypes S1/S1 + S1/X; (2) S3D, consisting of S3D/S3D + S3D/X; and (3) S1/S3D, consisting of S1/S1 + S1/X + S3D/S3D + S3D/X + S1/S3D. The high-risk genotype groups were (1) S2, consisting of genotypes S2/S2 + S2/X; (2) S3P, consisting of S3P/S3P + S3P/X; and (3) S2/S3P, consisting of S2/S2 + S2/X + S3P/S3P + S3P/X + S2/S3P. As shown in Table [7](#T7){ref-type="table"}, these comparisons revealed a highly significant risk associated with the S2/S3P, S3P and S1/S3D groups and, to a lesser extent, S1 and S3D as described in previous studies \[[@B21],[@B40]\]. No predisposing effect associated with RF seropositivity was identified, which confirms that the SE alleles are primarily associated with aCCP.

###### 

Predisposing effect of shared epitope genotypes on anticyclic citrullinated peptide antibody and rheumatoid factor seropositivity

                     aCCP               RF                              
  ------------------ ------------------ ------------ ------------------ --------
  S1 (*n*= 24)       2.4 (1.1 to 5.4)   0.0113\*     1.6 (0.9 to 2.9)   0.1245
  S3D (*n*= 17)      2.3 (1.0 to 5.4)   0.0287\*     1.7 (0.9 to 3.0)   0.1059
  S1/S3D (*n*= 50)   2.3 (1.0 to 5.3)   0.0049\*\*   1.6 (0.9 to 2.9)   0.0611
  S2 (*n*= 11)       2.2 (0.9 to 5.2)   0.0995       1.6 (0.9 to 3.1)   0.1930
  S3P (*n*= 28)      2.5 (1.1 to 5.6)   0.0075\*\*   1.6 (0.9 to 3.0)   0.0563
  S2/S3P (*n*= 47)   2.4 (1.1 to 5.5)   0.0025\*\*   1.6 (0.9 to 2.8)   0.0687

aCCP = anticyclic citrullinated peptide antibodies; RF = rheumatoid factor; SE = shared epitope. OR (95% CI) and *P*values were calculated using Fisher\'s exact test to compare rheumatoid arthritis patients with RA patients with the X/X genotype (*n*= 12). \**P*\< 0.05. \*\**P*≤ 0.008 values are highly significant. Groups S1, S3D, S2 and S3P consisted of the pooled homozygotes (SS) and heterozygotes (SX) for each group. Group S1/S3D consisted of S1/S1, S1/X, S3D/S3D, S3D/X and S1/S3D. Group S2/S3P consisted of S2/S2, S2/X, S3P/S3P, S3P/X and S2/S3P.

Relationship of shared epitope with other circulating biomarkers and clinical markers of disease activity
---------------------------------------------------------------------------------------------------------

Analysis (one-way ANOVA and Mann-Whitney *U*test) of the median values of the other circulating biomarkers and clinical markers of disease activity revealed significant associations with CRP (SS vs SX vs XX: *P*= 0.0041; SS vs SX: *P*= 0.0018), SAA (SS vs SX vs XX: *P*= 0.0018; SS vs SX: *P*= 0.0005), TNF (SS vs SX vs XX: *P*= 0.0295), IL-1Ra (SS vs XX: *P*= 0.0311) and DAS28 (SS vs SX vs XX: *P*= 0.0324; SS vs XX: *P*= 0.0103; SX vs XX: *P*= 0.0210). These trends were also noted with regard to most of the other cytokines, although they were not statistically significant (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12, CCL4, G-CSF, GM-GSF and IFN-γ).

Statistical comparison of the S1, S2, S3D and S3P groups did not reveal any significant differences, but in general the highest means for acute phase reactants, proinflammatory or anti-inflammatory cytokines, chemokines and VEGF were located predominantly in the SS-associated groups (data not shown).

Discussion
==========

Relatively few studies have been undertaken to evaluate the occurrence of RA-associated HLA-DRB1 alleles in southern African people with RA. The results of the current study, on the basis of high-resolution typing procedures in combination with the du Montcel HLA-DRB1 SE classification system \[[@B7]\], reveal that the incidence of RA risk-associated alleles in a population of predominantly black South African females with RA is comparable to or higher than those reported in European and Japanese populations \[[@B19]-[@B21]\] and somewhat higher than those reported in the relatively few studies undertaken in African Americans, which range from 25% to 40% \[[@B35]-[@B37]\]. Our data are in agreement with those of an earlier study where low-resolution PCR typing procedures were used, in which HLA-DRB1\*04 conferred the most significant risk of RA in a cohort of black South African RA patients \[[@B38]\]. According to the du Montcel classification system \[[@B7]\], the highest risk of RA is associated with the S2 and S3P alleles. Recently, Barnetche *et al*. \[[@B19]\] reported an association between RA susceptibility and HLA-DRB1 alleles (categorized according to the du Montcel classification system \[[@B7]\]) in a combined analysis of worldwide samples (1,210 cases of RA), which included 23 San people of southern African origin. Although the number of cases was small, 52.2% of the patients were found to be carriers of the S2 RA susceptibility allele compared to 26% in the control group (OR = 3.05) \[[@B19]\]. In addition, in agreement with previous European and Japanese RA cohort studies \[[@B19],[@B40]\], we observed highly significant associations of SS and SX with seropositivity for aCCP but not RF \[[@B21],[@B40]\]. We have previously reported that isolated measurement of aCCP is no more accurate than RF in the serodiagnosis of RA \[[@B41]\]. However, when used in combination with SE genotyping, measurement of aCCP appears to distinguish a subset of patients who may differ with respect to response to therapy and outcome.

These observations appear to support the relationship between HLA-DRB1 SE subtypes, presentation of citrullinated epitopes and development of RA \[[@B42]\]. This contention is underscored by the broad associations of circulating cytokines with the du Montcel classification system risk phenotype \[[@B7]\]. SS is most strongly associated with T-helper cell 1 (GM-CSF, TNF, IFN-γ and IL-2), Th2 (IL-4 and IL-6) and macrophage (IL-1β, IL-6, IL-8, IL-12, TNF and VEGF) cytokines, as well as with IL-1Ra. We and others have previously reported that RA is associated with a generalised increase in circulating proinflammatory and anti-inflammatory cytokines and chemokines, which might be compatible with Th1, macrophage and fibroblast activation and a counterregulatory role of Th2 cells \[[@B22],[@B23],[@B43]\].

Our findings are somewhat at variance with those recently reported by Singwe-Ngandeu *et al*. \[[@B44]\] in a relatively small group of Cameroonian RA patients (*n*= 56). Thirty percent of the RA patients in their study were either SS or SX compared to 10% in patients with other inflammatory rheumatic diseases and 14% in healthy controls. However, no significant associations between SE positivity (SS or SX) and aCCP or RF were detected. Several possible reasons might explain the differences between their study and our present study. Notwithstanding the relatively small number of patients, these differences include the number of alleles typed (21 in Singwe-Ngandeu *et al*. vs 43 in our present study) and, most importantly, the effects of chemotherapy. Whereas the patients in our study were corticosteroid- and DMARD-naïve at the time of presentation, the patients in the Singwe-Ngandeu *et al*. study were receiving prednisone (91%), methotrexate (77%), sulfasalazine (12%), azathioprine (5%), leflunomide (5%) and D-penicillamine (2%). Although this difference may explain the absence of associations of SE alleles with aCCP and RF, it is unlikely to explain the differences in frequencies of SE alleles detected in the two studies. Notwithstanding the larger number of alleles typed in the current study, it is also possible that our patients represent those at the extreme end of the severe disease spectrum. In the health care setting of the developing world, the presentation of patients to specialised RA clinics, of which there are few, is likely to be delayed, and our study cohort may therefore reflect a selection bias of patients seen in a tertiary setting.

Conclusions
===========

The results of the current study demonstrate an increased frequency of high-risk SE alleles in a predominantly black South African population with RA. We have also shown a clear association of high-risk SE alleles with aCCP in particular, to a lesser extent with RF, with circulating cytokines and chemokines and possibly with disease severity.
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